Daré Bioscience(DARE) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update *Please see below for important safety and other information. Ovaprene® Phase 3 Study Ovaprene is a novel, investigational hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer HealthCare. Working with study collaborators at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of ...